drugset / Trial / NCT00696241
Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine the safety and efficacy of azilsartan medoxomil, once daily (QD), compared to placebo and olmesartan in participants with essential hypertension.
Timeline
- Start
- 2007-06
- Primary completion
- 2008-10
- Completion
- 2008-10
Outcome
Met primary endpoint
registry Azilsartan Medoxomil 80 mg QD vs Placebo QD; p <0.001; Mean Difference (Final Values) -13.21 (95% CI -15.62 to -10.81) NCT00696241 ↗
paper Reduction in 24-hour mean SBP was greater with AZL-M 80 mg than OLM-M 40 mg by 2.1 mm Hg (95% confidence interval, -4.0 to -0.1; P=.038) PMID 21272195 ↗
Publications
- Results White WB, Weber MA, Sica D, Bakris GL, Perez A, Cao C, Kupfer S. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension. 2011 Mar;57(3):413-20. doi: 10.1161/HYPERTENSIONAHA.110.163402. Epub 2011 Jan 31.
- Results Bakris GL, Sica D, Weber M, White WB, Roberts A, Perez A, Cao C, Kupfer S. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens (Greenwich). 2011 Feb;13(2):81-8. doi: 10.1111/j.1751-7176.2010.00425.x.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azilsartan medoxomil | Other / unclassified | 20 mg | Oral |
| Subject | Azilsartan medoxomil | Other / unclassified | 40 mg | Oral |
| Subject | Azilsartan medoxomil | Other / unclassified | 80 mg | Oral |
| Subject | Olmesartan | Other / unclassified | 40 mg | Oral |